Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06576375
PHASE3

Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome

Sponsor: Future University in Egypt

View on ClinicalTrials.gov

Summary

In PCOS (Polycystic Ovary Syndrome), studies have found impaired incretin secretion and activity, particularly in overweight/obese individuals. Conflicting results exist regarding glucagon-like peptide-1(GLP-1) levels in PCOS patients, with studies reporting reduced, normal, or increased levels. Incretin-based therapy has been suggested as a potential treatment to reverse prediabetes risk by preserving β-cell function in patients with impaired fasting glucose(IFG and impaired glucose tolerance(IGT). The study aims to compare the efficacy of Dapagliflozin to Metformin for the treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).

Official title: Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome: A Prospective Comparative Randomized Blinded Trial.

Key Details

Gender

FEMALE

Age Range

18 Years - 40 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2024-09-02

Completion Date

2025-01

Last Updated

2024-10-22

Healthy Volunteers

No

Interventions

DRUG

Dapagliflozin

oral Dapagliflozin

DRUG

Metformin

oral metformin

Locations (1)

October 6 University Hospital

Giza, Egypt